Current News

	Search for:		in:

Target:

Full text

Titel

Company name

Division:

Country:

From:

To:

Operation:		OR		AND
Search for:		partial		exact

Overview

Companies

Countries

Symphogen attracts new usd 25 million investment

10 Jan 2006 - Symphogen A/S announced the initial closing of a USD 25 million Series D financing at a premium to the last financing round. The financing will be used to carry out clinical trials of Symphogen's first product, anti-RhD for the treatment of Idiopathic Thrombocytopenic Purpura (ITP) and engage in additional partnerships to leverage Symphogen's unique human polyclonal and monoclonal antibody discovery

and production capabilities.

�

Additional information

Symphogen A/S
Lyngby, Denmark

Company

Buyer's Guide entry of Symphogen A/S

�

News

	12 Aug 2008 -	CMC Biologics A/S Announce Manufacturing Agreement with Symphogen A/S
	21 Apr 2008 -	Biovitrum and Symphogen Initiates a Second Clinical study with a Novel Treatment of Hemolytic Diseases
	07 Feb 2008 -	Biovitrum and Symphogen have Successfully Completed Phase I Clinical Trial with Recombinant Polyclonal Antibody
�more news